Skip to Content
chevron-left chevron-right chevron-up chevron-right chevron-left arrow-back star phone quote checkbox-checked search wrench info shield play connection mobile coin-dollar spoon-knife ticket pushpin location gift fire feed bubbles home heart calendar price-tag credit-card clock envelop facebook instagram twitter youtube pinterest yelp google reddit linkedin envelope bbb pinterest homeadvisor angies

Invest in CAR T Cells

White blood cells are our bodies defense warriors, specifically produced to fight off infections and diseases. A type of white blood cell, a T cell, is an important part of this defense system. Two types of T cells exist: helper T cells and killer T cells. Helper cells recognize an antigen (foreign substance), mark the antigen for attack, and act as a messenger by telling/activating the killer T cells (they also activate another type of white blood cell, a B cell). Once the message is received and antigen identified, the killer T cells march into action by killing the infected cells. You can think of T cells as special soldiers, with helper cells looking out for the enemy and killer cells destroying them.

However, the one disease that can allude T cells is cancer, as they don’t always recognize and/or attack them, which in turn may allow for the development of tumors.

Chimeric antigen receptor T cells, or CAR T cells, is a technology that was created to remedy this. CAR T cells are engineered T cells created with chimeric antigen receptors (a super receptor) on their surface. This is done by extracting T cells from the human body and engineering them in a laboratory. Once back in the bloodstream, these new CAR T cells act as a super soldier that may assist the body in seeking and destroying cancer cells.

CAR T Cells

It seems that everyone knows at least one person who has been diagnosed with Cancer. The disease has been an elusive one for the healthcare industry for decades and even with billions spent on research, cancer is still the second leading cause of death worldwide. As most cancer patients must utilize a combination of therapies, with radiation and chemotherapy being the most widespread, the need for more efficient and safer treatments has led to a spark of innovation within the industry.

The most talked about technology to emerge in the field of immunotherapy is the use of CAR T cells which is being hyped as possibly the treatment to cure cancer. Although still only in its infancy, CAR T cell therapy is garnering a lot of attention from the healthcare industry.

Major Development

  • The summer of 2017 marked a milestone not only for the healthcare industry, but more specifically, the CAR T cell market. In a landmark decision, Novartis (NYSE: NVS) was granted the first ever FDA approval for use of a CAR T cell-based therapy when their treatment, Kymriah received the nod.
  • In the fall of 2017, a few short months after the Kymriah announcement, biopharmaceutical company Kite Pharma won the second CAR T cell-based therapy approval when their drug Yescarta won approval to treat adults with certain types of large B-cell lymphoma. During this time frame, Kite Pharma would go on to be acquired by Gilead Sciences (NYSE: GILD) for $11.9 billion in an all-cash deal. The purchase price of $180 a share represented a 30% premium from its prior days closing price and was 1,000% above the IPO price of $17 a share three years earlier
  • Already one of the biggest oncology pharma companies in the world, Celgene (NYSE: BMY – Celgene was acquired by Bristol-Meyer Squibb marking the largest pharma deal in history in January 2019 ) looked to make their presence known in the CAR T cell industry when in the winter of 2018 they acquired CAR T cell biopharmaceutical Juno Therapeutics. In one of Celgene’s largest deals ever, Juno was purchased for $9 billion at $87 a share, a 30% premium of the prior days closing price and 300% above Juno’s IPO price of $24 a share three years earlier

The Future

As evident in the acquisitions of Kite Pharma and Juno Therapeutics (and the hefty prices paid), the market for CAR T cell therapy is heating up. Based on research by Coherent Market Insights, the CAR T cell market is anticipated to reach a valuation of $3.3 billion by 2027.

Although CAR T cell therapy use is currently only isolated to adults with B-cell lymphoma and children with acute lymphoblastic leukemia, other cancers are now being looked at for the next phase of CAR T cell clinical trials. As we’re only a two years past the first FDA approval for the use of CAR T cell therapy, there still is much to learn from this revolutionary technology. That being said, with the CAR T cell industry under the lens of practically all major biopharma companies and media outlets alike, we should expect to hear more regarding the field of CAR T cell therapy

CAR T Cell Stocks

Industry: Drug ManufacturersGeneral

Sector: Healthcare

Website: http://www.novartis.com

Description: Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Its Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, established, and cardiovascular, renal and metabolism medicine products. The company’s Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has collaboration agreements with Pear Therapeutics; Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute; Science 37; Bill & Melinda Gates Foundation; Amgen; University of California, Berkeley; Bristol-Myers Squibb; Drugs for Neglected Diseases initiative (DNDi); TScan Therapeutics; Dyno Therapeutics Inc.; and Olema Oncology. The company was founded in 1895 and is headquartered in Basel, Switzerland.

Fundamentals
Market cap$196.05B
P/E ratio24.69
Earnings per share$3.52
Return on equity14.39%
Profit margin16.22%
Total revenue$49.76B
Debt / Equity67.15
Price / Book3.47
52 week high$98.52
52 week low$77.04
Shares outstanding$2.26B
Previous close$86.30
Dividend Analysis
Dividend yield3.71%
Payout ratio87.71%
Trailing Annual Dividend Rate$3.40
Five Year Avg Dividend Yield3.42%
Ex-Dividend dateMarch 3, 2021 6:00 PM

Industry: Drug ManufacturersGeneral

Sector: Healthcare

Website: http://www.gilead.com

Description: Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company’s products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.

Fundamentals
Market cap$82.95B
P/E ratio672.24
Earnings per share$0.10
Return on equity0.43%
Profit margin0.50%
Total revenue$24.69B
Debt / Equity176.26
Price / Book4.54
52 week high$85.79
52 week low$56.56
Shares outstanding$1.26B
Previous close$65.60
Dividend Analysis
Dividend yield4.33%
Payout ratio2,720.00%
Trailing Annual Dividend Rate$2.72
Five Year Avg Dividend Yield3.19%
Ex-Dividend dateMarch 11, 2021 6:00 PM

Industry: Drug ManufacturersGeneral

Sector: Healthcare

Website: http://www.bms.com

Description: Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company’s products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor to treat human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, Ubiquigent Limited, Checkmate Pharmaceuticals, and Sensyne Health plc; clinical collaboration with NeoImmuneTech, Inc.; partnership with Astrazeneca Plc; a discovery collaboration with Insitro, Inc.; and collaboration with Schrdinger, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Fundamentals
Market cap$139.06B
P/E ratio
Earnings per share$ -3.99
Return on equity-20.08%
Profit margin-21.20%
Total revenue$42.52B
Debt / Equity136.43
Price / Book3.69
52 week high$67.16
52 week low$54.07
Shares outstanding$2.23B
Previous close$62.06
Dividend Analysis
Dividend yield3.16%
Payout ratio0.00%
Trailing Annual Dividend Rate$1.84
Five Year Avg Dividend Yield2.84%
Ex-Dividend dateMarch 30, 2021 7:00 PM

Industry: Biotechnology

Sector: Healthcare

Website: http://www.bluebirdbio.com

Description: bluebird bio, Inc., a biotechnology company, engages in researching, developing, and commercializing of transformative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin for the treatment of -thalassemia and sickle cell disease; and Lenti-D for the treatment of cerebral adrenoleukodystrophy. The company’s product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Bristol-Myers Squibb to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; Forty Seven, Inc. to pursue clinical proof-of-concept for an antibody-based conditioning regimen; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Fundamentals
Market cap$1.97B
P/E ratio
Earnings per share$ -9.95
Return on equity-46.87%
Profit margin-246.75%
Total revenue$250.73M
Debt / Equity14.25
Price / Book1.44
52 week high$72.51
52 week low$24.24
Shares outstanding$67.14M
Previous close$30.02
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.bellicum.com

Description: Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company’s clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. It has collaboration and license agreements with Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.

Fundamentals
Market cap$29.17M
P/E ratio
Earnings per share$ -1.34
Return on equity-143.13%
Profit margin0.00%
Total revenue$500.00K
Debt / Equity7.52
Price / Book
52 week high$9.56
52 week low$2.62
Shares outstanding$8.32M
Previous close$3.49
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

ndustry: Biotechnology

Sector: Healthcare

Website: http://www.ziopharm.com

Description: ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient’s immune system to attack cancer cells. It is developing Ad-RTS-hIL-12 plus veledimex, which is in Phase 2 clinical trial, to treat patients with recurrent glioblastoma multiforme in adults. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; collaboration with MD Anderson targeting CD19 on malignant B cells using Sleeping Beauty platform; and research and development agreement with the National Cancer Institute to evaluate autologous peripheral blood lymphocytes, and Ares Trading S.A. The company was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Fundamentals
Market cap$725.57M
P/E ratio
Earnings per share$ -0.38
Return on equity-73.04%
Profit margin0.00%
Total revenue$0.00
Debt / Equity3.88
Price / Book5.83
52 week high$5.95
52 week low$2.06
Shares outstanding$214.67M
Previous close$3.38
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.sorrentotherapeutics.com

Description: Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. In addition, the company’s clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases. Further, it develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Additionally, the company engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. It has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, as well as a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento’s COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.

Fundamentals
Market cap$2.11B
P/E ratio
Earnings per share$ -1.30
Return on equity-362.46%
Profit margin0.00%
Total revenue$39.99M
Debt / Equity120.37
Price / Book12.16
52 week high$19.39
52 week low$2.18
Shares outstanding$280.86M
Previous close$7.58
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.allogene.com

Description: Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. It is also developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. Allogene Therapeutics, Inc. also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of AlloCAR T candidates across a portfolio of hematologic and solid tumors. The company was founded in 2017 and is headquartered in South San Francisco, California.

Fundamentals
Market cap$4.69B
P/E ratio
Earnings per share$ -2.08
Return on equity-29.29%
Profit margin0.00%
Total revenue$0.00
Debt / Equity4.98
Price / Book4.34
52 week high$55.00
52 week low$21.18
Shares outstanding$140.65M
Previous close$32.88
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.atarabio.com

Description: Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and viral diseases, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; ATA230 for cytomegalovirus; ATA368 for HPV; ATA520 for Wilms Tumor 1; and ATA621 for BK and JCV. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was founded in 2012 and is headquartered in South San Francisco, California.

Fundamentals
Market cap$1.20B
P/E ratio
Earnings per share$ -4.14
Return on equity-81.43%
Profit margin0.00%
Total revenue$0.00
Debt / Equity3.28
Price / Book2.58
52 week high$28.20
52 week low$7.45
Shares outstanding$83.61M
Previous close$14.20
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.beamtx.com

Description: Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.

Fundamentals
Market cap$4.62B
P/E ratio
Earnings per share$ -4.19
Return on equity-112.32%
Profit margin0.00%
Total revenue$24.00K
Debt / Equity43.84
Price / Book17.09
52 week high$126.90
52 week low$14.80
Shares outstanding$61.63M
Previous close$74.37
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.cellectis.com

Description: Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.

Fundamentals
Market cap$837.54M
P/E ratio
Earnings per share$ -1.91
Return on equity-29.35%
Profit margin-98.32%
Total revenue$82.46M
Debt / Equity34.54
Price / Book3.02
52 week high$34.71
52 week low$9.15
Shares outstanding$42.78M
Previous close$19.44
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.cellbiomedgroup.com

Description: Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company’s CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.

Fundamentals
Market cap$384.69M
P/E ratio
Earnings per share$
Return on equity0.00%
Profit margin0.00%
Total revenue$0.00
Debt / Equity
Price / Book
52 week high$19.76
52 week low$11.48
Shares outstanding$0.00
Previous close$19.75
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.fatetherapeutics.com

Description: Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company’s NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

Fundamentals
Market cap$7.24B
P/E ratio
Earnings per share$ -2.10
Return on equity-55.11%
Profit margin0.00%
Total revenue$31.43M
Debt / Equity25.31
Price / Book17.62
52 week high$121.16
52 week low$25.37
Shares outstanding$93.78M
Previous close$75.70
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.fortressbiotech.com

Description: Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ximino to treat inflammatory lesions of severe acne vulgaris. It also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial product that reduces amyloid deposits in the tissues and organs; MB-102, a chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; MB-106, a CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, the company develops MB-101 for Glioblastoma multiform (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB 108 for GBM; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101 that is in Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; Cosibelimab for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; AVTS-001, an adeno-associated virus gene therapy; CUTX-101, a copper histidinate injection for the treatment of Menkes disease; CK-103 for metastatic solid tumor cancers; CK-302 for oncology indications; and CK-303 to treat renal cell carcinoma. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.

Fundamentals
Market cap$445.12M
P/E ratio
Earnings per share$ -0.65
Return on equity-76.42%
Profit margin-102.03%
Total revenue$45.60M
Debt / Equity45.22
Price / Book4.43
52 week high$5.08
52 week low$1.88
Shares outstanding$94.88M
Previous close$4.24
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.mustangbio.com

Description: Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develop MB-107, a gene therapy program, potential curative treatment for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. Its ex vivo lentiviral gene therapy is in two Phase 1/2 clinical trials. The company also develops MB-102, a heterodimeric interleukin-3-receptor for acute myeloid leukemia; MB-106 for immunotherapy of B-cell lymphomas; MB-104, an NK cell receptor regulating immune functions; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has a license agreement with Nationwide Children’s Hospital for the development of an oncolytic virus for treating GBM; and Beth Israel Deaconess Medical Center, Inc. to perform research relating to gene editing. The company was incorporated in 2015 and is headquartered in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.

Fundamentals
Market cap$276.82M
P/E ratio
Earnings per share$ -1.14
Return on equity0.00%
Profit margin-79.97%
Total revenue$0.00
Debt / Equity2.26
Price / Book2.36
52 week high$5.22
52 week low$2.42
Shares outstanding$64.75M
Previous close$3.18
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.nektar.com

Description: Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops NKTR-181, a novel mu-opioid analgesic drug, which is in Phase III clinical trial for chronic low back pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I is designed to provide rapid activation and proliferation of cancer-killing CD8+ effector T cells and NK cells. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for oncology; and NKTR-255, which is in phase I for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain; CIMZIA for crohn’s disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

Fundamentals
Market cap$3.55B
P/E ratio
Earnings per share$ -2.49
Return on equity-35.80%
Profit margin-290.64%
Total revenue$152.92M
Debt / Equity13.95
Price / Book3.26
52 week high$26.75
52 week low$15.40
Shares outstanding$182.29M
Previous close$19.62
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.precisionbiosciences.com

Description: Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome-editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and PBCAR20A, an allogeneic anti-CD20 CAR T for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products. The company has a development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; and a collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.

Fundamentals
Market cap$494.03M
P/E ratio
Earnings per share$ -2.09
Return on equity-119.30%
Profit margin0.00%
Total revenue$24.29M
Debt / Equity23.68
Price / Book10.28
52 week high$16.60
52 week low$4.46
Shares outstanding$56.99M
Previous close$8.92
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Load More

Contact Us For Opportunities in the Private Market